Spero Therapeutics Announces 3Q17 Operating Results and Pipeline Update

Raised approximately $83.6 million in gross proceeds from Initial Public Offering Advanced pipeline with initiation of SPR994 Phase 1 trial in October 2017 and SPR741 Phase 1b trial in November 2017 CAMBRIDGE, Mass. , Dec. 14, 2017 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc.


Leave a Reply

Your email address will not be published.